Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers
Chitre et al.,
Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2..,
Phytotherapy Research, doi:10.1002/ptr.7683, CTRI/2020/09/027817
RCT 208 moderate COVID-19 patients in India, 103 treated with a combination of turmeric, ashwagandha, boswellia, and ginger, showing improved recovery with treatment. The dose of curcumin is unknown and bioavailability may be poor.
recovery time, 11.3% lower, relative time 0.89, p = 0.04, treatment 89, control 86.
|
fever, 11.0% lower, RR 0.89, p = 0.03, treatment 70 of 89 (78.7%), control 76 of 86 (88.4%), NNT 10, day 4.
|
congestion, 20.0% lower, RR 0.80, p = 0.05, treatment 89, control 86, mid-recovery, day 7.
|
sore throat, 20.0% lower, RR 0.80, p = 0.09, treatment 89, control 86, mid-recovery, day 7.
|
cough, 14.3% lower, RR 0.86, p = 0.14, treatment 89, control 86, mid-recovery, day 7.
|
dyspnea, 15.4% lower, RR 0.85, p = 0.15, treatment 89, control 86, mid-recovery, day 7.
|
pain, 8.3% lower, RR 0.92, p = 0.41, treatment 89, control 86, mid-recovery, day 7.
|
fatigue, 16.7% lower, RR 0.83, p = 0.13, treatment 89, control 86, mid-recovery, day 7.
|
headache, 16.7% lower, RR 0.83, p = 0.12, treatment 89, control 86, mid-recovery, day 7.
|
chills, 18.2% lower, RR 0.82, p = 0.09, treatment 89, control 86, mid-recovery, day 7.
|
diarrhea, 25.0% lower, RR 0.75, p = 0.08, treatment 89, control 86, mid-recovery, day 7.
|
vomiting, 18.2% lower, RR 0.82, p = 0.07, treatment 89, control 86, mid-recovery, day 7.
|
smell, 16.7% lower, RR 0.83, p = 0.06, treatment 89, control 86, mid-recovery, day 7.
|
taste, 16.7% lower, RR 0.83, p = 0.14, treatment 89, control 86, mid-recovery, day 7.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Chitre et al., 23 Nov 2022, Double Blind Randomized Controlled Trial, placebo-controlled, India, peer-reviewed, 8 authors, this trial uses multiple treatments in the treatment arm (combined with ashwagandha, boswellia, ginger) - results of individual treatments may vary, trial CTRI/2020/09/027817.
Contact:
dchitre@bioved.com, snadkarni@bioved.com.
Abstract: Revised: 17 October 2022
Accepted: 25 October 2022
DOI: 10.1002/ptr.7683
RESEARCH ARTICLE
Phase III randomized clinical trial of BV-4051, an Ayurvedic
polyherbal formulation in moderate SARS-CoV-2 infections
and its impact on inflammatory biomarkers
Deepa Chitre 1
| Satej Nadkarni 1
Amol Gitte 4
| Prashant Rahate 5
1
Bioved Pharmaceuticals, Inc., San Jose,
California, USA
|
|
Namdev Jagtap 2
Sunetra Chaskar 6
| Rahul Tulle 3
|
| Debendranath Dey 1
Abstract
2
Vishwaraj Hospital, Loni Kalbhor, Pune, India
SARS-CoV-2 virus and its variants continue to be a challenge inspite of widespread
3
Vedant Hospital, Thane, Mumbai, India
vaccination and preventive measures. We hypothesized an oral, safe polyherbal for-
4
Siddhivinayak Hospital, Thane, Mumbai, India
5
Seven Star Hospital, Nagpur, India
6
Bioved Pharmaceuticals Pvt. Ltd., Pune, India
mulation with antiinflammatory properties may improve the clinical outcome of this
disease. BV-4051, a formulation from four Ayurvedic plants namely Ashwagandha,
Boswellia, Ginger and Turmeric was used for the treatment of hospitalized moderate
Correspondence
Deepa Chitre, Bioved Pharmaceuticals, Inc.,
1929 O'Toole Way, San Jose, CA 95131, USA.
Email: dchitre@bioved.com
COVID-19 patients along with standard of care (SOC). Patients were randomly
assigned to receive BV-4051 or placebo tablets for 14 days, at four sites in India during late 2020 to early 2021. Among 208 randomized subjects, 175 completed the
study. In BV-4051 group the mean reduction in duration of illness (p = 0.036), alleviation and severity scores of several symptoms like fever, cough, smell, and taste disorders were statistically significant (p ≤ 0.05). A sub-set analysis of subjects treated
with or without Remdesivir as SOC showed mean reduction in duration of illness in
BV-4051 (p = 0.030), and severity scores (p ≤ 0.05). Mean difference in Interleukin-6
was statistically significant (p = 0.042) on BV-4051 without Remdesivir. BV-4051
may reduce duration of illness, symptoms severity, Interleukin-6, and prevent the
incidence of COVID-19 complications. It may have an adjunctive effect with other
SOC. Larger extensive clinical testing may give a better understanding of its effect.
KEYWORDS
ARTOVID-20®, Ayurveda, Covid-19, herbal, interleukin-6, Remdesivir
1
|
I N T RO DU CT I O N
certain populations in developed nations, the disease and its variants
continue to cause significant morbidity, mortality, and economic
Aggressive global vaccination efforts, widespread public healthcare
impact (World Bank Report, 2022).
measures, and a better understanding of treatment modalities provide
Immune hyperactivation in COVID-19 is precipitated by a surge
a significant improvement in the management of the SARS-CoV2 pan-
of critical immune mediators including Tumor Necrosis Factor (TNF),
demic. However, in many developing countries and also among
Interferon-Gamma (IFN-γ), and Interleukin-6 (IL-6) that leads to respiratory failure, shock, and multi-organ dysfunction (Ablamunits &
Clinical Trials Registry of India: CTRI/2020/09/027817.
Lepsy, 2022; Herold et al., 2020; Mandel et al., 2020). There have
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2022 Bioved Pharmaceuticals, Inc. Phytotherapy Research published by John Wiley & Sons Ltd.
Phytotherapy Research...
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit